BBV154

BBV154
Vaccine description
TargetSARS-CoV-2
Vaccine typeViral vector
Clinical data
Routes of
administration		Intranasal
ATC code
  • None

BBV154 is an intranasal COVID-19 vaccine candidate developed by Bharat Biotech,[1][2] American company Precision Virologics[3][4] and the Washington University School of Medicine in St Louis, Missouri, United States.[5][6]

Clinical trials

Phase I trials

On recommendation by the Subject Expert Committee (SEC) under the Indian drug regulator, the company is going to conduct phase 1 clinical trials using 75 volunteers and submit safety and immunogenicity data for the committee’s consideration before it proceeds to the second phase of the trial.[7]

Phase II and III trials

On 12 August 2021, after evaluating the results of phase I trial data, the drug regulator approved for phase II/III randomized trials that involves evaluation of the immunogenicity and safety of Covaxin with BBV154 in healthy volunteers.[8]

References

  1. ↑ Clinical trial number NCT04751682 for "Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19" at ClinicalTrials.gov
  2. ↑ "Intranasal Vaccine For Covid-19". Bharat Biotech. Retrieved 5 March 2021.
  3. ↑ "St. Louis-based Precision Virologics and India's Biotech leader Bharat Biotech obtain rights to intranasal COVID-19 vaccine technology". www.biostl.org. Retrieved 29 August 2021.
  4. ↑ Hassan, AO; Kafai, NM; Dmitriev, IP; Fox, JM; Smith, BK; Harvey, IB; Chen, RE; Winkler, ES; Wessel, AW; Case, JB; Kashentseva, E; McCune, BT; Bailey, AL; Zhao, H; VanBlargan, LA; Dai, YN; Ma, M; Adams, LJ; Shrihari, S; Danis, JE; Gralinski, LE; Hou, YJ; Schäfer, A; Kim, AS; Keeler, SP; Weiskopf, D; Baric, RS; Holtzman, MJ; Fremont, DH; Curiel, DT; Diamond, MS (1 October 2020). "A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2". Cell. 183 (1): 169–184.e13. doi:10.1016/j.cell.2020.08.026. PMC 7437481. PMID 32931734.
  5. ↑ "Bharat Biotech to make a billion doses of an intranasal adenovirus vaccine". The Indian Express. 23 September 2020. Archived from the original on 3 May 2021. Retrieved 23 September 2020.
  6. ↑ "Bharat Biotech Partners With US University For Covid Intranasal Vaccine". NDTV.com. Archived from the original on 3 May 2021. Retrieved 23 September 2020.
  7. ↑ Raghavan P (30 January 2021). "Explained: Understanding BBV154, Bharat Biotech's single-dose intranasal Covid-19 vaccine". The Indian Express.
  8. ↑ Gaurav, Kunal (13 August 2021). "First nasal vaccine developed by Bharat Biotech gets nod for Phase 2/3 trial". Hindustan Times.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.